Bridge Back to Life to Offer Hythiam's PROMETA Treatment Protocol in Three Initial Locations; New York Based Treatment Center to Offer PROMETA among Six Clinics Located in Manhattan and Clinics in Long Island and Staten Island.

LOS ANGELES -- Hythiam, Inc. (NASDAQ:HYTM), which licenses the PROMETA(TM) protocols designed to target the biology of substance dependence, announced today that the PROMETA protocols have been licensed to the highly renowned Bridge Back To Life Centers in the greater New York metropolitan area.

Tom Markoski D.O., Philip Gianelli M.D. and Lyubov Gorelick M.D. will administer PROMETA at Bridge Back to Life Center clinics located in Manhattan, Long Island, and Staten Island. Bridge Back to Life has a total of six facilities in New York City. As a whole, the center treats between 1,200 -- 1,500 patients per week for substance dependency disorders and over 100 counselors are staffed to also provide cognitive group and individual therapy to patients.

"We believe PROMETA will be a remarkable adjunct to what we can offer the city in combating the serious substance abuse problem that is confronting various populations in New York, including business people; the gay community; and the younger people active in the club scene," said Gary Butchen, President of the Bridge Back to Life network. "Bridge Back to Life has made its reputation by being on the cutting edge. As treatments like PROMETA emerge, we continue to investigate the outcomes and incorporate those that show positive results into our treatment options."

"We welcome Bridge Back to Life as our partner," said Terren S. Peizer, Hythiam's Chairman and CEO. "We look forward to working with them in providing service to the substance dependent populations of Manhattan, Long Island, and Staten Island. Together we will work to provide further options for East Coast addiction treatment providers for the benefit of those who suffer from this disease."

About PROMETA

Hythiam's PROMETA treatment protocols are designed for use by healthcare providers seeking to treat individuals diagnosed with dependencies to alcohol, cocaine or methamphetamines, as well as combinations of these drugs. The PROMETA treatment protocols comprise FDA-approved oral and IV medications used off-label and separately administered in a unique dosing algorithm, as well as nutritional supplements combined with psychosocial or other recovery-oriented therapy chosen by the patient and their treatment provider. As a result, PROMETA represents an innovative approach to managing alcohol, cocaine or methamphetamine dependence that is designed to address physiological, nutritional and psychosocial aspects of the disease, and is thereby intended to offer patients an opportunity to achieve sustained recovery.

About Hythiam, Inc.

Hythiam(R) is focused on delivering solutions for those suffering from alcoholism and other substance dependencies. Hythiam researches, develops, licenses and commercializes innovative physiological treatment protocols that seek to address substance dependence. Additionally, Hythiam provides proprietary administrative services to assist physicians and facilities with staff education, marketing and sales support, and outcomes tracking for data analysis. For further information, please click on www.hythiam.com.

About Bridge Back to Life

Since 1988, Bridge Back to Life has achieved a reputation for quality treatment of addictive disorders. The center offers day and evening hours six days per week. Masters and Doctoral level therapists provide quality care in most treatment modalities, including group, individual, and family psychotherapies. All patients receive a comprehensive evaluation prior to beginning treatment. This evaluation culminates into an individualized treatment plan for each person. This may include crisis intervention services, psychiatric evaluation, medication management, intensive outpatient programs, and a variety of other collateral services. In addition, the centers pride themselves on being culturally sensitive offering treatment services in several languages including Spanish, Russian, Mandarin, Cantonese, and Polish.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history and lack of statistically significant formal research studies, the risk that treatment protocols might not be effective, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and substantial regulation in the healthcare industry; and additional risks factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at http://www.sec.gov.